Search

Your search keyword '"Neelapu, Sattva S"' showing total 1,695 results

Search Constraints

Start Over You searched for: Author "Neelapu, Sattva S" Remove constraint Author: "Neelapu, Sattva S"
1,695 results on '"Neelapu, Sattva S"'

Search Results

1. Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

2. Cytokine Release Syndrome Following CD19 Directed Chimeric Antigen Receptor T-Cell Therapy

3. List of Contributors

4. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial

5. Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial

7. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium

8. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

9. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

10. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

11. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

12. Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy

13. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease

14. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

15. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.

16. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL

17. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma

19. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma

20. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

21. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights

23. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma

24. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab

28. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells

29. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

31. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

32. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

33. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

35. Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B‐cell lymphoma after 2 or more lines of prior therapy

36. Analysis of Colonic FDG Uptake and Association with Response and Toxicity to CART in LBCL Patients

37. Clinical Factors Associated with Failure to Manufacture Commercial CAR-T Cell Products Among LBCL Patients

39. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma

40. CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity

41. Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer

43. Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies.

44. Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.

46. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma

47. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities

49. A comparison of 3-year follow-up of ZUMA-5 (axicabtagene ciloleucel) with SCHOLAR-5 in relapsed/refractory follicular lymphoma

50. Role of the tumor microenvironment in mature B-cell lymphoid malignancies

Catalog

Books, media, physical & digital resources